In this study, we hypothesized that targeting the genetic variability in PTGS2, ABCC4, HPGD, and SLCO2A1, main players in the PGE2 pathway, would enable the identification of susceptibility biomarkers for GC onset. This evidence concerns the gene SLCO2A1 and gastric cancer.